Spread of Tau Protein in Alzheimer's Patients Measured As Disease Progresses
Tau deposits in the brain of a patient with early-stage Alzheimer’s disease. The warm colours indicate regions of heavy deposition and the difference in spread between the patient’s first scan (left) and second scan 17 months later (right). Nordberg Group, Karolinska Institutet, Sweden.
In a new study presented in Molecular Psychiatry, researchers at Karolinska Institutet have measured how deposits of the pathological protein tau spread through the brain over the course of Alzheimer’s disease. Their results show that the size of the deposit and the speed of its spread differ from one individual to the next, and that large amounts of tau in the brain can be linked to episodic memory impairment.
Already in a very early phase of Alzheimer’s disease there is an accumulation of tau in the brain cells, where its adverse effect on cell function causes memory impairment. It is therefore an attractive target for vaccine researchers. For the present study, Professor Agneta Nordberg at Karolinska Institutet’s Department of Neurobiology, Care Sciences and Society and her doctoral student Konstantinos Chiotis along with the rest of her team used PET brain imaging to measure the spread of tau deposits as well as the amyloid plaque associated with Alzheimer’s disease, and charted the energy metabolism of the brain cells. They then examined how these three parameters changed over the course of the disease.
“There’s been an international race to measure tau spread, and we probably got there first,” says Professor Nordberg. “There are no previous reports on how tau deposits spread after 17 months into the disease. Our results can improve understanding of tau accumulation in Alzheimer’s disease, help ongoing research to quantify the effect of tau vaccines, and enable early diagnosis.”
The study included 16 patients at different stages of Alzheimer’s disease from the memory unit at Karolinska Hospital in Huddinge. The patients were given a series of neurological memory tests and underwent PET scans at 17-month intervals. While all 16 participants had abundant amyloid plaque deposition in the brain, the size and speed of spread of their tau deposits differed significantly between individuals.
Episodic memory impairment
“We also saw a strong direct correlation between size of deposit and episodic memory impairment,” continues Professor Nordberg. “This could explain why the disease progresses at such a varying rate from one patient to the other. That said, tau doesn’t seem to have much of an effect on the global general memory, which is more reasonably related to brain metabolism.”
The study was conducted in collaboration with Uppsala University, where the PET scans were performed.
The study was financed by the Swedish Research Council, the Swedish Foundation for Strategic Research, Stockholm County Council (ALF funds), the Strategic Research Area in neuroscience at Karolinska Institutet, the Gamla Tjänarinnor Foundation, the Axel Linder Foundation, the Gun and Bertil Stohne Foundation, KI’s Funds, the Swedish Brain Fund, the Swedish Alzheimer’s Foundation, the Swedish Dementia Foundation, the Wenner-Gren Foundations, KTH – SCC research grants and the EU INMiND project.
Chiotis, K., Saint-Aubert, L., Rodriguez-Vieitez, E., Leuzy, A., Almkvist, O., Savitcheva, I., Jonasson, M., Lubberink, M., Wall, A., Antoni, G. and Nordberg, A. (2017). Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia. Molecular Psychiatry.
This article has been republished from materials provided by Karolinska Institutet. Note: material may have been edited for length and content. For further information, please contact the cited source.
Two Proteins Dictate Visual System Axon StabilizationNews
Scientists have made an important discovery concerning the development of layer-specific axonal connections in the developing visual system of Drosophila flies.READ MORE
Metabolomic Profiling Identifies Taurine as New MS TherapeuticNews
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies. The discovery also highlights the potential for a technique called “metabolomic profiling,” which can identify useful endogenous metabolites the body already makes in small quantities, such as taurine, for new applications in drug therapies.READ MORE